146 related articles for article (PubMed ID: 20005964)
1. Early elevation of C-reactive protein correlates with severe infection and nonrelapse mortality in children undergoing allogeneic stem cell transplantation.
McNeer JL; Kletzel M; Rademaker A; Alford K; O'Day K; Schaefer C; Duerst R; Jacobsohn DA
Biol Blood Marrow Transplant; 2010 Mar; 16(3):350-7. PubMed ID: 20005964
[TBL] [Abstract][Full Text] [Related]
2. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
4. Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children.
Schneider DT; Lemburg P; Sprock I; Heying R; Göbel U; Nürnberger W
Bone Marrow Transplant; 2000 May; 25(10):1079-86. PubMed ID: 10828869
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Patterns of C-reactive protein release following allogeneic stem cell transplantation are correlated with leukemic relapse.
Min CK; Kim SY; Eom KS; Kim YJ; Kim HJ; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2006 Mar; 37(5):493-8. PubMed ID: 16435015
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of C-reactive protein after allogeneic bone marrow transplantation identifies patients at risk of severe transplant-related complications and mortality.
Schots R; Kaufman L; Van Riet I; Lacor P; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 1998 Jul; 22(1):79-85. PubMed ID: 9678800
[TBL] [Abstract][Full Text] [Related]
8. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes.
Majhail NS; Parks K; Defor TE; Weisdorf DJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1038-46. PubMed ID: 17067910
[TBL] [Abstract][Full Text] [Related]
9. Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM).
Bacigalupo A; Oneto R; Bruno B; Lamparelli T; Gualandi F; Bregante S; Raiola AM; Di Grazia C; Dominietto A; Lombardi A; Frassoni F; Van Lint MT
Bone Marrow Transplant; 2001 Dec; 28(11):1041-5. PubMed ID: 11781614
[TBL] [Abstract][Full Text] [Related]
10. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.
de Pagter PJ; Schuurman R; Visscher H; de Vos M; Bierings M; van Loon AM; Uiterwaal CS; van Baarle D; Sanders EA; Boelens J
Biol Blood Marrow Transplant; 2008 Jul; 14(7):831-9. PubMed ID: 18541204
[TBL] [Abstract][Full Text] [Related]
11. Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease.
Großekatthöfer M; Güclü ED; Lawitschka A; Matthes-Martin S; Mann G; Minkov M; Peters C; Seidel MG
Ann Hematol; 2013 Aug; 92(8):1121-8. PubMed ID: 23604429
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.
Kanda J; Mizumoto C; Kawabata H; Ichinohe T; Tsuchida H; Tomosugi N; Matsuo K; Yamashita K; Kondo T; Ishikawa T; Uchiyama T
Biol Blood Marrow Transplant; 2009 Aug; 15(8):956-62. PubMed ID: 19589485
[TBL] [Abstract][Full Text] [Related]
13. Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation.
Diaz MA; Vicent MG; Prudencio M; Rodriguez F; Marin C; Serrano A; Sevilla J; Casado J; Madero L
Haematologica; 2002 Mar; 87(3):292-8. PubMed ID: 11869942
[TBL] [Abstract][Full Text] [Related]
14. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation.
Ferrà C; de Sanjosé S; Gallardo D; Berlanga JJ; Rueda F; Marìn D; de la Banda E; Ancìn I; Peris J; Garcìa J; Grañena A
Haematologica; 1998 Dec; 83(12):1082-7. PubMed ID: 9949625
[TBL] [Abstract][Full Text] [Related]
15. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience.
Berman JN; Wang M; Berry W; Neuberg DS; Guinan EC
Bone Marrow Transplant; 2006 Jan; 37(1):73-80. PubMed ID: 16247423
[TBL] [Abstract][Full Text] [Related]
16. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
17. Severe metabolic abnormalities after allogeneic hematopoietic cell transplantation.
Lee JH; Choi SJ; Lee JH; Kim SE; Seol M; Lee YS; Lee JS; Kim WK; Lee KH
Bone Marrow Transplant; 2005 Jan; 35(1):63-9. PubMed ID: 15502852
[TBL] [Abstract][Full Text] [Related]
18. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation.
Schots R; Van Riet I; Othman TB; Trullemans F; De Waele M; Van Camp B; Kaufman L
Bone Marrow Transplant; 2002 Oct; 30(7):441-6. PubMed ID: 12368956
[TBL] [Abstract][Full Text] [Related]
19. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
20. Secondary failure of platelet recovery after hematopoietic stem cell transplantation.
Bruno B; Gooley T; Sullivan KM; Davis C; Bensinger WI; Storb R; Nash RA
Biol Blood Marrow Transplant; 2001; 7(3):154-62. PubMed ID: 11302549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
